AIM Immunotech
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • CEO Corner
    • Partnering
  • Science
    • Pipeline
    • Ampligen®
    • Immuno-Oncology
    • Immune Disorders
    • Viral Diseases
    • Orphan Drug Designation
    • Scientific Publications
  • Investors
    • Overview
    • Press Releases
    • Company Info
      • Profile
      • Management Team
    • Presentations
    • Events
    • Stock Information
    • SEC Filings
    • Analyst Coverage
    • Corporate Governance
      • Governance Documents
      • Board of Directors
      • Committee Composition
    • Stockholder Meeting
    • Email Alerts
    • Investor Contact
  • Contact Us
Select Page

Science

Recent Posts

  • AIM ImmunoTech Announces the Presentation of Ampligen Oncology Data at the Recent Annual Meeting of the American Association of Immunologists
  • AIM ImmunoTech Announces Trading Under the Ticker AIMI on the Pink Open Market
  • AIM ImmunoTech Announces NYSE American Notice of Delisting and Appeal
  • AIM ImmunoTech Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
  • AIM ImmunoTech Inc. Participates in the Virtual Investor “Top 5 for ’25” On-Demand Conference

Recent Comments

No comments to show.
Get Notified

Sign up to have the latest news and information delivered directly to your inbox!

Sign Up Now

Contact Us

AIM ImmunoTech
2117 SW Highway 484
Ocala, FL 34473
Phone: 352-448-7797
Fax: 352-480-4620
Email: info@AIMimmuno.com

Investor Relations Contact
JTC Team, LLC
Jenene Thomas
908-824-0775
AIM@jtcir.com

©2025 AIM ImmunoTech     All Rights Reserved
  • Privacy Policy
  • Terms of Use
  • Follow
  • Follow
  • Follow